Organon (OGN) Other Operating Expenses (2020 - 2026)
Organon (OGN) recorded quarterly Other Operating Expenses of $96.0 million in Q1 2026, up 45.45% quarter-over-quarter from $66.0 million in Q4 2025, and up 900.0% on a YoY basis from $9.6 million in Q1 2025.
Organon (OGN) Other Operating Expenses (2020 - 2026) Analysis & Trends
Organon's Other Operating Expenses history runs 7 years deep, the most recent figure standing at $96.0 million for Q1 2026.
- In Q1 2026, Other Operating Expenses rose 900.0% year-over-year to $96.0 million; the TTM figure through Mar 2026 stood at $227.0 million (up 856.67% YoY), while the FY2025 annual figure was $119.0 million, up 666.67% from the prior year.
- Other Operating Expenses was $96.0 million for Q1 2026 at Organon, up from $66.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $96.0 million in Q1 2026 to a low of -$12.0 million in Q4 2024.
- Historically, Other Operating Expenses has averaged $10.9 million across 5 years, with a median of -$4.0 million in 2022.
- The sharpest annual moves came in 2024 and 2026: Other Operating Expenses slumped 500.0% in 2024, then surged 900.0% in 2026.
- A 5-year view of Other Operating Expenses shows it stood at -$4.0 million in 2022, then changed by 0.0% to -$4.0 million in 2023, then tumbled by 200.0% to -$12.0 million in 2024, then surged by 650.0% to $66.0 million in 2025, then surged by 45.45% to $96.0 million in 2026.
- The last three Other Operating Expenses figures came in at $96.0 million (Q1 2026), $66.0 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | 66.00 Mn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 35.00 Mn |
| Mar 31, 2025 | -12.00 Mn |
| Dec 31, 2024 | -12.00 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | -4.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | -7.00 Mn |
| Mar 31, 2022 | -4.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Sep 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -20.00 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | 53.00 Mn |